Key result
Direct oral anticoagulants are evaluated as promising alternatives to vitamin K antagonists in patients with stable coronary artery disease, acute coronary syndrome, or undergoing percutaneous coronary intervention.
Why the study?
Determining the optimal anticoagulation strategy for patients with CAD, ACS, or undergoing PCI remains challenging, as recurrent event risks persist with antiplatelet therapy and vitamin K antagonists have notable shortcomings.
Are direct oral anticoagulants effective alternatives to vitamin K antagonists in patients with stable coronary artery disease, acute coronary syndrome, or undergoing percutaneous coronary intervention?
Are direct oral anticoagulants effective alternatives to vitamin K antagonists in patients with stable coronary artery disease, acute coronary syndrome, or undergoing percutaneous coronary intervention?
This review summarizes the evidence for using direct oral anticoagulants in patients with coronary artery disease, acute coronary syndromes, and those undergoing revascularization.
The investigation for the optimal anticoagulation strategy for patients with stable coronary artery disease, acute coronary syndromes, and undergoing percutaneous coronary intervention constitutes a great challenge for physicians and is a field of extensive research. Although aspirin is commonly recommended as a protective measure for all patients with coronary artery disease and dual antiplatelet therapy for those undergoing procedures, such as percutaneous coronary intervention or coronary artery bypass graft surgery, the risk of recurrent cardiovascular events remains significant. In this context, the shortcomings associated with the use of vitamin K antagonists have led to the assessment of direct oral anticoagulants as promising alternatives. This review will explore and provide a comprehensive analysis of the existing data regarding the use of direct oral anticoagulants in patients with stable coronary artery disease or acute coronary syndrome, as well as their effectiveness in those undergoing percutaneous coronary intervention or coronary artery bypass graft surgery.
No takes yet. Share an insight, caveat, or question.
Sagris et al. (2023) conducted a review in Stable coronary artery disease, acute coronary syndrome, or undergoing percutaneous coronary intervention. Direct oral anticoagulants vs. Vitamin K antagonists was evaluated. Direct oral anticoagulants are evaluated as promising alternatives to vitamin K antagonists in patients with stable coronary artery disease, acute coronary syndrome, or undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: